(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of -0.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Ideaya Biosciences's revenue in 2026 is $225,270,000.On average, 19 Wall Street analysts forecast IDYA's revenue for 2026 to be $2,931,040,291, with the lowest IDYA revenue forecast at $0, and the highest IDYA revenue forecast at $7,887,714,093. On average, 17 Wall Street analysts forecast IDYA's revenue for 2027 to be $10,868,395,804, with the lowest IDYA revenue forecast at $5,166,222,096, and the highest IDYA revenue forecast at $15,843,081,094.
In 2028, IDYA is forecast to generate $19,715,990,448 in revenue, with the lowest revenue forecast at $10,118,063,547 and the highest revenue forecast at $34,108,487,753.